Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Nabil K. Thalji, MD PhD, Prakash A Patel, MD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 3640.

https://doi.org/10.1182/blood-2019-125955

Published: 2019

Journal Articles

Treatment and Outcomes in Heparin-Induced Thrombocytopenia (HIT) in Patients with Neoplasm: A Single Centre Experience

Chieh Min Lai, MD PhD, Tyler Smith, MD, Agnes Yuet Ying Lee, MD MSc, FRCPC

Blood (2019) 134 (Supplement_1): 4951.

https://doi.org/10.1182/blood-2019-122389

Published: 2019

Journal Articles

Are We Doing Too Many HIT Tests III?

Syed Zia-ur-Rehman Shah, MD BPharm, Seshan Subramanian, MD

Blood (2018) 132 (Supplement 1): 2444.

https://doi.org/10.1182/blood-2018-99-110035

Published: 2018

Journal Articles

Incidence of Thrombocytopenia and Heparin Induced Thrombocytopenia in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Compared to Cardiopulmonary Bypass and the Limited Sensitivity of Pre-Test Probability Score

Deepa Jayakody Arachchillage, MD MRCP, FRCPath, Sanjay Khanna, Christophe Vandenbriele, Jonthan Dutton, Alex Rosenberg, MRCP, FCICM, FFICM, TC Aw, FRCA, Winston Banya, Maurizio Passariello, EDIC, Michael Laffan, DM, FRCP, FRCPath, Stephane Ledot, EDIC, MD, Brijesh Patel, MRCP, FRCA, FFICM , PhD

Blood (2018) 132 (Supplement 1): 2451.

https://doi.org/10.1182/blood-2018-99-119143

Published: 2018

Journal Articles

A Restructured Approach to Diagnosis of Heparin Induced Thrombocytopenia in a Large Tertiary Hospital

Sriman Swarup, MD MBBS, Somedeb Ball, MD, Nimesh Adhikari, MD, Courtney Alice Welch, Jaden Fackrell, MS, Kyaw Zin Thein, MD MBBS, Anita Sultan, MD, Khatrina Swarup, RN, Sanjay Awasthi, MD, Lukman Tijani, MD

Blood (2018) 132 (Supplement 1): 3525.

https://doi.org/10.1182/blood-2018-99-114265

Published: 2018

Journal Articles

The Risk of Major Bleeding in Patients with Suspected Heparin-Induced Thrombocytopenia (HIT)

Allyson Pishko, MD, Daniel Lefler, MD, Phyllis Gimotty, PhD, James Guevara, MD MPH, Adam Cuker, MD MS

Blood (2018) 132 (Supplement 1): 377.

https://doi.org/10.1182/blood-2018-99-112200

Published: 2018

Journal Articles

Hypofibrinogenemia in Patient with Extended Exposure to Argatroban Therapy

Mustafa Saudi, MD

Blood (2018) 132 (Supplement 1): 5035.

https://doi.org/10.1182/blood-2018-99-117765

Published: 2018

Journal Articles

A Single Institution's Adherence to Heparin-Induced Thrombocytopenia and Thrombosis Testing Guidelines

Kristine Gade, MD BS, Jack Melson, MD, Alex Jepsen, MD, Surabhi Palkimas, PharmD, Bethany Horton, PhD, Hillary S. Maitland, MD MS

Blood (2018) 132 (Supplement 1): 4720.

https://doi.org/10.1182/blood-2018-99-117132

Published: 2018

Journal Articles

Appropriateness of Heparin-Induced Thrombocytopenia (HIT) Testing and the Reliability of 4-Ts Scoring in Critically Ill Patients

Phyo Thazin Myint, MDMSc, Amani Erra, MD, Taha Alrifai, MD, Salman Syed, MD, Bibek Singh Pannu, MD, Shyam Chalise, MD, Kelley E. Kozma, DO

Blood (2018) 132 (Supplement 1): 4988.

https://doi.org/10.1182/blood-2018-99-114788

Published: 2018

Journal Articles

Comparison of Rivaroxaban with Argatroban in Heparin Induced Thrombocytopenia Using Historical Controls : A Case-Control Study

Vivek Suresh Modi, MBBS, Karan Jatwani, MBBS, Sridevi Rajeeve, MD, Gaurav Kakked, MBBS, MS, Hardikumar Patel, mbbs, Dhrubajyoti Bandyopadhyay, MBBS, MD, Siva Krishna Mannem, MBBS

Blood (2018) 132 (Supplement 1): 4996.

https://doi.org/10.1182/blood-2018-99-120364

Published: 2018

Journal Articles

Utilizing the Predictive Value of the 4T Scoring System to Reduce Unnecessary HIT Panel Costs in the Community Hospital Setting

Rashmika Potdar, MBBS, Sorab Gupta, MD, Jia Hwei Ng, Schoepe Robert, Andrew Berson, Reena Bansal, Kamran Mohiuddin, Mylene Sy Go

Blood (2018) 132 (Supplement 1): 5001.

https://doi.org/10.1182/blood-2018-99-110683

Published: 2018

Journal Articles

Confirmation of the Utility of the 4T Scoring System for HIT

Zachary Trisel, MD, Mark Maddox, DO, Ahmed Safa, MD, Thomas Bemis, MD, Kristine Ward, MD, Michael Styler, MD

Blood (2018) 132 (Supplement 1): 5816.

https://doi.org/10.1182/blood-2018-99-119573

Published: 2018

Journal Articles

Recognizing the Existence of Heparin Induced Thrombocytopenia and Thrombosis in the Setting of High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Case Series

Shayna Sarosiek, MD, Karen Quillen, MDMPH, John Mark Sloan, MD, Dina Brauneis, NP, Vaishali Sanchorawala, MD

Blood (2017) 130 (Supplement 1): 3643.

https://doi.org/10.1182/blood.V130.Suppl_1.3643.3643

Published: 2017

Journal Articles

A 2 Year of Review of HIT Evaluations at an Urban Medical Center with an Aim Towards Quality Improvement and the Development of Practical Testing Strategies

Stephen Zachary Peeke, MD, Ilan Shapira, MD, Ismini Kourouni, MD

Blood (2017) 130 (Supplement 1): 2322.

https://doi.org/10.1182/blood.V130.Suppl_1.2322.2322

Published: 2017

Journal Articles

Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States

Ahmed Aljabri, Yvonne Huckleberry, Jason H. Karnes, Mahdi Gharaibeh, Hussam I. Kutbi, Yuval Raz, Seongseok Yun, Ivo Abraham, Brian Erstad

Blood (2016) 128 (26): 3043–3051.

https://doi.org/10.1182/blood-2016-07-728030

Published: 2016

Journal Articles

HIT the price point with fondaparinux

Nathan T. Connell

Blood (2016) 128 (26): 3019–3020.

https://doi.org/10.1182/blood-2016-11-750513

Published: 2016

Journal Articles

Heparin-Induced Thrombocytopenia Antibody Testing and Its Cost Effectiveness: Taking a Financial HIT

Anusiyanthan Isaac Mariampillai, MD, Josephine Pineda Dela Cruz, MD, Harry Staszewski, MD, Nina D'Abreo, MD

Blood (2016) 128 (22): 2343.

https://doi.org/10.1182/blood.V128.22.2343.2343

Published: 2016

Journal Articles

Intravenous Immunoglobulin (IVIg) Is a Highly Effective Treatment for HIT: Critical Role of the IgG Fc Domain in Inhibiting HIT Antibody-Mediated Platelet Activation

Anand Padmanabhan, MBBS, MA, PhD, Curtis G Jones, Shannon M Pechauer, Barbara J. Bryant, MD, Jack B. Alperin, MD, Mehraboon S. Irani, MBBChir, Binod Dhakal, MDMS, Brian R Curtis, PhD D(ABMLI) MT(ASCP)SBB, Daniel W. Bougie, PhD, Mia J Sullivan, Renren Wen, PhD, Demin Wang, PhD, Richard H. Aster, MD

Blood (2016) 128 (22): 2600.

https://doi.org/10.1182/blood.V128.22.2600.2600

Published: 2016

Journal Articles

Evidence of Thrombin-Independent Generation of Activated Protein C

Heiko Rühl, MD, Janine Rossa, Christina Berens, MD, Anna Winterhagen, Johannes Oldenburg, Prof, Jens Müller, PhD, Bernd Pötzsch, MD PhD

Blood (2016) 128 (22): 2568.

https://doi.org/10.1182/blood.V128.22.2568.2568

Published: 2016

Journal Articles

Novel Class of Direct Thrombin Inhibitors Prevent Thrombosis By Inhibiting Fibrinogen Cleavage While Preserving Platelet Function

Mohan Sivaraja, PhD, Sivan Sizikov, PhD, Nichole Sandoval, Kenneth Lin, PhD, Lev Igoudin, Subhadra Dash, MSc, Chengpei Xu, MD PhD, Daniel Clemens, PhD, Angels Estiarte, PhD, Timothy Shiau, PhD, Kevin Short, PhD, David Williams, PhD, Anirban Datta, PhD, David Kita, PhD

Blood (2016) 128 (22): 3834.

https://doi.org/10.1182/blood.V128.22.3834.3834

Published: 2016

NARROW

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Treatment and Outcomes in Heparin-Induced Thrombocytopenia (HIT) in Patients with Neoplasm: A Single Centre Experience

Are We Doing Too Many HIT Tests III?

Incidence of Thrombocytopenia and Heparin Induced Thrombocytopenia in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Compared to Cardiopulmonary Bypass and the Limited Sensitivity of Pre-Test Probability Score

A Restructured Approach to Diagnosis of Heparin Induced Thrombocytopenia in a Large Tertiary Hospital

The Risk of Major Bleeding in Patients with Suspected Heparin-Induced Thrombocytopenia (HIT)

Hypofibrinogenemia in Patient with Extended Exposure to Argatroban Therapy

A Single Institution's Adherence to Heparin-Induced Thrombocytopenia and Thrombosis Testing Guidelines

Appropriateness of Heparin-Induced Thrombocytopenia (HIT) Testing and the Reliability of 4-Ts Scoring in Critically Ill Patients

Comparison of Rivaroxaban with Argatroban in Heparin Induced Thrombocytopenia Using Historical Controls : A Case-Control Study

Utilizing the Predictive Value of the 4T Scoring System to Reduce Unnecessary HIT Panel Costs in the Community Hospital Setting

Confirmation of the Utility of the 4T Scoring System for HIT

Recognizing the Existence of Heparin Induced Thrombocytopenia and Thrombosis in the Setting of High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Case Series

A 2 Year of Review of HIT Evaluations at an Urban Medical Center with an Aim Towards Quality Improvement and the Development of Practical Testing Strategies

Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States

HIT the price point with fondaparinux

Heparin-Induced Thrombocytopenia Antibody Testing and Its Cost Effectiveness: Taking a Financial HIT

Intravenous Immunoglobulin (IVIg) Is a Highly Effective Treatment for HIT: Critical Role of the IgG Fc Domain in Inhibiting HIT Antibody-Mediated Platelet Activation

Evidence of Thrombin-Independent Generation of Activated Protein C

Novel Class of Direct Thrombin Inhibitors Prevent Thrombosis By Inhibiting Fibrinogen Cleavage While Preserving Platelet Function

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only